

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

½ c â h ç ø l □ Ê î ¼ Z ï Y 0 ¥ ï / p ... d 4 \ l Æ ø

**Staple your
payment
here
請將股款
緊釘在此**

This Application Form uses the same terms as defined in the prospectus of Simcere Pharmaceutical Group Limited (the “**Company**”) dated October 13, 2020 (the “**Prospectus**”).

本申請表格使用先聲藥業集團有限公司（「**本公司**」）於2020年10月13日刊發的招股書（「**招股書**」）所界定的詞語。Neither this Application Form nor the Prospectus constitutes an offer to sell or the solicitation of an offer to buy any Hong Kong Offer Shares in any jurisdiction other than Hong Kong. The Hong Kong Offer Shares may not be offered or sold in the United States without registration or an exemption from registration under the U.S. Securities Act.

本申請表格及招股書概不構成在香港以外任何司法管轄區要約出售或游說要約購買任何香港發售股份。若無根據美國證券法登記或豁免登記，香港發售股份不得在美國提呈發售或出售。

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction.

在任何根據當地法例不得發送、派發或複製本申請表格及招股書的司法管轄區內概不得發送或派發或複製（不論方式，也不論全部或部分）本申請表格及招股書。

Copies of the Prospectus, all related Application Forms and the other documents specified in the “Documents Delivered to the Registrar of Companies and Available for Inspection – Documents Delivered to the Registrar of Companies” section in Appendix VI to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 38D of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Hong Kong Securities Clearing Company Limited (“**HKSCC**”), the Securities and Futures Commission of Hong Kong (the “**SFC**”) and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents.

招股書、所有相關申請表格及招股書附錄六「送呈公司註冊處處長及備查文件—送呈公司註冊處處長文件」一節所述其他文件已遵照香港法例第32章公司（清盤及雜項條文）條例第38D條的規定，送呈香港公司註冊處處長登記。香港交易及結算有限公司、香港聯合交易所有限公司（「**聯交所**」）、香港中央結算有限公司（「**香港結算**」）、香港證券及期貨事務監察委員會（「**證監會**」）及香港公司註冊處處長對此等文件的內容概不負責。

Simcere Pharmaceutical Group Limited **先聲藥業集團有限公司**

(Incorporated in Hong Kong with limited liability)
(於香港註冊成立的有限公司)

Stock Code : 2096

股份代號 : 2096

Maximum Offer Price : HK\$13.70 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)

最高發售價：每股發售股份13.70港元，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費（須於申請時以港元繳足，多繳款項可予退還）

You should read this Application Form in conjunction with the Prospectus, which contains further information on the application procedures.

招股書尚有關於申請程序的其他資料，本申請表格應與招股書一併閱讀。

Application Form 申請表格

To: Simcere Pharmaceutical Group Limited
Joint Sponsors
Joint Global Coordinators
Joint Bookrunners
Hong Kong Underwriters

致：先聲藥業集團有限公司
聯席保薦人
聯席全球協調人
聯席賬簿管理人
香港包銷商

Applicants' declaration

I/We agree to the terms and conditions and application procedures in this Application Form and the Prospectus. Please refer to the “Effect of completing and submitting this Application Form” section of this Application Form.

Warning: Only one application may be made for the benefit of any person. Please refer to the last four bullets of “Effect of completing and submitting this Application Form” section.

申請人聲明

本人／吾等同意本申請表格及招股書的條款及條件以及申請程序。請參閱本申請表格「填交本申請表格的效用」一節。

警告：任何人士只限作出一次為其利益而進行的認購申請。請參閱「填交本申請表格的效用」一節最後四點。

Signed by (all) applicant(s) (all joint applicants must sign):
由(所有)申請人簽署(所有聯名申請人必須簽署):

For Broker use 此欄供經紀填寫					Lodged by 遞交申請的經紀	
Broker No. 經紀號碼					Broker's Chop 經紀印章	

Cheque/banker's cashier order number 支票／銀行本票號碼
--

Name of bank on which cheque/banker's cashier order is drawn
(see "How to make your application" section) 兌現支票／銀行本
票的銀行名稱（見「申請手續」一節）

Date 日期: / /
D日 M月 Y年

Number of Hong Kong Offer Shares applied for (not more than 13,029,000 Shares)
申請香港發售股份數目（不超過13,029,000股股份）

--

Total amount 總額

HK\$	港元
------	----

Name in English (in BLOCK letters) 英文姓名／名稱（以正楷填寫）

Family name or company name 姓氏或公司名稱	Forename(s) 名字
-------------------------------------	----------------

Name in Chinese 中文姓名／名稱

Family name or company name 姓氏或公司名稱	Forename(s) 名字
-------------------------------------	----------------

Occupation in English 職業 (以英文填寫)

--

Hong Kong Identity Card No./Passport No./Hong Kong Business
Registration No.* (Please delete as appropriate) 香港身份證號碼／護
照號碼／香港商業登記號碼* (請刪除不適用者)

--

Names of all other joint applicants in English (if any, in BLOCK letters)
所有其他聯名申請人的英文姓名／名稱（如有，以正楷填寫）

1)
2)
3)

Hong Kong Identity Card No./Passport No./Hong Kong Business Registration No.
of all other joint applicants* (Please delete as appropriate) 所有其他聯名申請人
的香港身份證號碼/護照號碼/香港商業登記號碼*(請刪除不適用者)

1)
2)
3)

Hong Kong address in English and telephone no. (joint applicants should give the address and the telephone number of first-named applicant only in BLOCK letters) 香港地址 (以英文正楷填寫) 及電話號碼 (聯名申請人只須填寫排名首位申請人的地址及電話號碼)

Telephone No. 電話號碼

For Nominees: You will be treated as applying for your own benefit if you do not complete this section. Please provide an account number or identification code for each (joint) beneficial owner. 由代名人遞交：代名人若不填寫本節，是項認購申請將視為閣下利益提出。請填寫每名（聯名）實益擁有人的賬戶號碼或識別編碼。

--

ADDRESS LABEL 地址標貼 (Your **name(s)** and **address** in Hong Kong in BLOCK letters 請用英文正楷填寫姓名／名稱及香港地址)

- * (1) An individual must provide his Hong Kong Identity Card number or, if he does not hold a Hong Kong Identity Card, his passport number. A body corporate must provide its Hong Kong Business Registration number. Each joint applicant must provide its or his relevant number. The Hong Kong Identity Card number(s)/passport number(s)/Hong Kong Business Registration number(s) will be transferred to a third party for checking the Application Form's validity.
個別人士須填寫其香港身份證號碼或（如非香港身份證持有人）護照號碼。法人團體須填寫其香港商業登記號碼。每名聯名申請人均須提供其相關號碼。該等香港身份證號碼／護照號碼／香港商業登記號碼將轉交第三方以核實申請表格的有效性。
- (2) Part of the Hong Kong Identity Card number/passport number of you or, for joint applicants, the first-named applicant may be printed on your refund cheque (if any). Your banker may require verification of your Hong Kong Identity Card number/passport number before you can cash your refund cheque.
日後如需退回申請股款，退款支票上或會印有閣下或（如屬聯名申請人）排名首位申請人的香港身份證號碼／護照號碼的一部分。銀行兌現退款支票前或會要求查證閣下的香港身份證號碼／護照號碼。
- (3) If an application is made by an unlisted company and:
- the principal business of that company is dealing in securities; and
 - you exercise statutory control over that company,
- then the application will be treated as being made for your benefit.
如申請人是一家非上市公司，而：
- 該公司的主要業務為證券買賣；及
 - 閣下可對該公司行使法定控制權，
- 是項申請將視作為閣下的利益提出。

This page is intentionally left blank
此乃白頁 特意留空

Please use this form if you want the Hong Kong Offer Shares to be issued in your name

How to make your application

1. Use the table below to calculate how much you must pay. Your application must be for a minimum of 1,000 Hong Kong Offer Shares and in one of the numbers set out in the table, or your application will be rejected.

4. Tear off the Application Form, fold it once and lodge your completed Application Form (with cheque or banker's cashier order attached) to one of the collection boxes at any of the following branches of:

Bank of China (Hong Kong) Limited

District	Branch Name	Address
Hong Kong Island	Shek Tong Tsui Branch	534 Queen's Road West, Shek Tong Tsui, Hong Kong
	409 Hennessy Road Branch	409-415 Hennessy Road, Wan Chai, Hong Kong
Kowloon	Mei Foo Mount Sterling Mall Branch	Shop N47-49, G/F, Mount Sterling Mall, Mei Foo Sun Chuen, Kowloon
	Kowloon Plaza Branch	Unit 1, Kowloon Plaza, 485 Castle Peak Road, Kowloon
New Territories	Tai Wai Branch	74-76 Tai Wai Road, Sha Tin, New Territories
	Castle Peak Road (Yuen Long) Branch	162 Castle Peak Road, Yuen Long, New Territories

5. Your Application Form can be lodged at these times:

Tuesday, October 13, 2020 – 9:00 a.m. to 5:00 p.m.
Wednesday, October 14, 2020 – 9:00 a.m. to 5:00 p.m.
Thursday, October 15, 2020 – 9:00 a.m. to 5:00 p.m.
Friday, October 16, 2020 – 9:00 a.m. to 12:00 noon

6. The latest time for lodging your application is 12:00 noon on Friday, October 16, 2020. The application lists will be opened between 11:45 a.m. to 12:00 noon on that day, subject only to the weather conditions, as described in "Effect of Bad Weather on the Opening of the Application Lists" in the "How to Apply for the Hong Kong Offer Shares" section of the Prospectus.

The applications for the Hong Kong Offer Shares will commence on Tuesday, October 13, 2020 through Friday, October 16, 2020. The application monies (including the brokerage fees, SFC transaction levies and Stock Exchange trading fees) will be held by the receiving bank and on behalf of the Company after the closing of the application lists and the refund monies, if any, will be returned to the applicants without interest on or before Thursday, October 22, 2020. Investors should be aware that the dealings in the Shares on the Stock Exchange are expected to commence on Friday, October 23, 2020.

如 閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

申請手續

1. 使用下表計算 閣下應付的款項。 閣下申請認購的股數須至少為1,000股香港發售股份，並為下表所列的其中一個數目，否則 閣下的申請將不獲受理。

先聲藥業集團有限公司 (每股香港發售股份13.70港元) 可供申請認購的香港發售股份數目及應繳款項							
申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元	申請認購的 香港發售 股份數目	申請時 應繳款項 港元
1,000	13,838.06	20,000	276,761.10	100,000	1,383,805.49	3,000,000	41,514,164.70
2,000	27,676.11	25,000	345,951.38	200,000	2,767,610.98	4,000,000	55,352,219.60
3,000	41,514.17	30,000	415,141.65	300,000	4,151,416.47	5,000,000	69,190,274.50
4,000	55,352.22	35,000	484,331.93	400,000	5,535,221.96	6,000,000	83,028,329.40
5,000	69,190.28	40,000	553,522.20	500,000	6,919,027.45	7,000,000	96,866,384.30
6,000	83,028.33	45,000	622,712.48	600,000	8,302,832.94	8,000,000	110,704,439.20
7,000	96,866.39	50,000	691,902.75	700,000	9,686,638.43	9,000,000	124,542,494.10
8,000	110,704.44	60,000	830,283.29	800,000	11,070,443.92	10,000,000	138,380,549.00
9,000	124,542.50	70,000	968,663.84	900,000	12,454,249.41	13,029,000 ⁽¹⁾	180,296,017.30
10,000	138,380.55	80,000	1,107,044.39	1,000,000	13,838,054.90		
15,000	207,570.83	90,000	1,245,424.94	2,000,000	27,676,109.80		

⁽¹⁾ 閣下可申請認購的香港發售股份最高數目。

2. 以英文正楷填妥及簽署表格。只接納親筆簽名（不得以個人印章代替）。
3. 閣下須將支票或銀行本票釘於表格上。每份香港發售股份申請須附一張獨立開出的支票或一張獨立開出的銀行本票。支票或銀行本票必須符合以下所有規定，否則 閣下的申請將不獲受理：

支票必須：	銀行本票必須：
- 為港元； - 不得為期票； - 註明抬頭人為「中國銀行（香港）代理有限公司－先聲藥業公開發售」； - 劃線註明「只准入抬頭人賬戶」；	
- 從 閣下在香港的港元銀行賬戶中開出；及 - 顯示 閣下的賬戶名稱，而該賬戶名稱必須已預印在支票上，或由有關銀行授權的人士在支票背書。賬戶名稱必須與 閣下姓名／名稱相同。如屬聯名申請，賬戶名稱必須與排名首位申請人的姓名／名稱相同。	須由香港持牌銀行開出，並由有關銀行授權的人士在銀行本票背面簽署核證 閣下姓名／名稱。銀行本票所示姓名／名稱須與 閣下姓名／名稱相同。如屬聯名申請，銀行本票背面所示姓名／名稱必須與排名首位申請人的姓名／名稱相同。

如 閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

4. 請撕下申請表格，對摺一次，然後將填妥的申請表格（連同支票或銀行本票）投入下列任何一家分行特設的收集箱：

中國銀行（香港）有限公司

地區	分行名稱	地址
香港島	石塘咀分行	香港石塘咀皇后大道西534號
	軒尼詩道409號分行	香港灣仔軒尼詩道409-415號
九龍	美孚萬事達廣場分行	九龍美孚新邨萬事達廣場地下N47-49號舖
	九龍廣場分行	九龍青山道485號九龍廣場1號
新界	大圍分行	新界沙田大圍道74-76號
	元朗青山道分行	新界元朗青山公路162號

5. 閣下可於下列時間遞交申請表格：

2020年10月13日（星期二） — 上午九時正至下午五時正
2020年10月14日（星期三） — 上午九時正至下午五時正
2020年10月15日（星期四） — 上午九時正至下午五時正
2020年10月16日（星期五） — 上午九時正至中午十二時正

6. 截止遞交申請的時間為2020年10月16日（星期五）中午十二時正。本公司將於當日上午十一時四十五分至中午十二時正期間開始辦理申請登記，唯一會影響此時間的變化因素為當日的天氣情況（詳見招股書「如何申請香港發售股份」一節「惡劣天氣對開始辦理申請登記的影響」）。

香港發售股份申請將會自2020年10月13日（星期二）起直至2020年10月16日（星期五）止。申請款項（包括經紀佣金、證監會交易徵費及聯交所交易費）將由收款銀行於截止辦理申請登記後代表本公司持有，且退款金額（如有）將於2020年10月22日（星期四）或之前不計利息退還予申請人。投資者務請注意，預期股份將於2020年10月23日（星期五）於聯交所開始買賣。



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

GLOBAL OFFERING

Conditions of your application

A. Who can apply

1. You and any person(s) for whose benefit you are applying must be 18 years of age or older and must have a Hong Kong address.
2. If you are a firm, the application must be in the individual members' names.
3. The number of joint applicants may not exceed four.
4. If you are a body corporate, the application must be signed by a duly authorised officer, who must state his or her representative capacity, and stamped with your corporation's chop.
5. You must be outside the United States, not be a United States Person (within the meaning of Regulation S under the U.S. Securities Act) or a person described in paragraph (h)(3) of Rule 902 of Regulation S under the U.S. Securities Act and not be a legal or natural person of the PRC.
6. Unless permitted by the Listing Rules or any relevant waivers that have been granted by the Stock Exchange, you cannot apply for any Hong Kong Offer Shares if you are:
 - an existing beneficial owner of shares in the Company and/or any of its subsidiaries;
 - a Director or chief executive officer of the Company and/or any of its subsidiaries;
 - a close associate of any of the above;
 - a connected person of the Company or will become a connected person of the Company immediately upon completion of the Global Offering; or
 - have been allocated or have applied for or indicated an interest in any Offer Shares under the International Offering.

B. If you are a nominee

You, as a nominee, may make more than one application for the Hong Kong Offer Shares by: (i) giving electronic application instructions to HKSCC via Central Clearing and Settlement System ("CCASS") (if you are a CCASS Participant); or (ii) using a **WHITE** or **YELLOW** Application Form, and lodge more than one application in your own name on behalf of different beneficial owners.

C. Effect of completing and submitting this Application Form

By completing and submitting this Application Form, you (and if you are joint applicants, each of you jointly and severally) for yourself or as an agent or a nominee on behalf of each person for whom you act:

- **undertake** to execute all relevant documents and instruct (or their agents or nominees), as agents of the Company, to execute any documents for you and to do on your behalf all things necessary to register any Hong Kong Offer Shares allocated to you in your name as required by the Articles of Association;
- **agree** to comply with the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) and the Articles of Association;
- **confirm** that you have read the terms and conditions and application procedures set out in the Prospectus and in this Application Form and agree to be bound by them;
- **confirm** that you have received and read the Prospectus and have only relied on the information and representations contained in the Prospectus in making your application and will not rely on any other information or representations except those in any supplement to the Prospectus;
- **confirm** that you are aware of the restrictions on the Global Offering in the Prospectus;
- **agree** that none of the Company, the Joint Sponsors, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, their respective directors, officers, employees, partners, agents, advisers and any other parties

involved in the Global Offering (the "**Relevant Persons**") and the **White Form eIPO** Service Provider is or will be liable for any information and representations not in the Prospectus (and any supplement to it);

- **undertake and confirm** that you or the person(s) for whose benefit you have made the application have not applied for or taken up, or indicated an interest for, and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor participated in the International Offering;
- **agree** to disclose to the Company, the Hong Kong Share Registrar, receiving bank and the Relevant Persons any personal data which they may require about you and the person(s) for whose benefit you have made the application;
- if the laws of any place outside Hong Kong apply to your application, **agree** and **warrant** that you have complied with all such laws and none of the Company nor the Relevant Persons will breach any law outside Hong Kong as a result of the acceptance of your offer to purchase, or any action arising from your rights and obligations under the terms and conditions contained in the Prospectus and this Application Form;
- **agree** that once your application has been accepted, you may not rescind it because of an innocent misrepresentation;
- **agree** that your application will be governed by the laws of Hong Kong;
- **represent, warrant and undertake** that (i) you understand that the Hong Kong Offer Shares have not been and will not be registered under the U.S. Securities Act; and (ii) you and any person for whose benefit you are applying for the Hong Kong Offer Shares are outside the United States (as defined in Regulation S) or are a person described in paragraph (h)(3) of Rule 902 of Regulation S;
- **warrant** that the information you have provided is true and accurate;
- **agree** to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to you under the application;
- **authorise** the Company to place your name(s) on the Company's register of members as the holder(s) of any Hong Kong Offer Shares allocated to you, and the Company and/or its agents to send any share certificate(s) and/or any refund cheque(s) to you or the first-named applicant for joint application by ordinary post at your own risk to the address stated on the application, unless you have fulfilled the criteria set out in "Personal Collection" in the "How to Apply for the Hong Kong Offer Shares" section in the Prospectus to collect the share certificate(s) and/or refund cheque(s) in person;
- **understand** that, in accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, where the International Offer Shares are undersubscribed and the Hong Kong Offer Shares are oversubscribed irrespective of the number

- **declare** and **represent** that this is the only application made and the only application intended by you to be made to benefit you or the person for whose benefit you are applying;
- (if the application is made for your own benefit) **warrant** that no other application has been or will be made for your benefit on a **WHITE** or **YELLOW** Application Form or by giving electronic application instructions to HKSCC or to the **White Form eIPO** Service Provider by you or by any one as your agent or by any other person; and
- (if you are making the application as an agent for the benefit of another person) **warrant** that (i) no other application has been or will be made by you as agent for or for the benefit of that person or by that person or by any other person as agent for that person on a **WHITE** or **YELLOW** Application Form or by giving electronic application instructions to HKSCC and (ii) you have due authority to sign the Application Form or give electronic application instructions on behalf of that other person as their agent.

D. Power of attorney

If your application is made through an authorised attorney, the Company and the Joint Global Coordinators may accept or reject your application at their discretion, and on any conditions they think fit, including evidence of the attorney's authority.

Determination of Offer Price and Allocation of Hong Kong Offer Shares

The Offer Price is expected to be fixed on or around Friday, October 16, 2020. Applicants are required to pay the maximum Offer Price of HK\$13.70 for each Hong Kong Offer Share together with 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee. If the Offer Price is not agreed among the Company and the Joint Global Coordinators (for themselves and on behalf of the Underwriters) on or before Thursday, October 22, 2020, the Global Offering will not proceed.

Applications for Hong Kong Offer Shares will not be processed and no allotment of any Hong Kong Offer Shares will be made until the application lists close.

The Company expects to announce the final Offer Price, the indication of the level of interest in the International Offering, the level of applications under the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Thursday, October 22, 2020 on the website of the Stock Exchange at www.hkexnews.hk and the Company's website at www.simcere.com. Results of allocations and the Hong Kong Identity Card/passport/Hong Kong business registration numbers of successful applicants (where applicable) will be available on the above websites.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation" in the Prospectus. In particular, the Joint Global Coordinators may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEx-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to Practice Note 18 of the Listing Rules, the number of Offer Shares that may be reallocated from the International Offering to the Hong Kong Public Offering shall not exceed 26,056,000 Shares, representing

70223S-2 TD0 0vTw T*[(under the Hong K)35(ong Public Of)25(f

如閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格



Sincere Pharmaceutical Group Limited

先聲藥業集團有限公司

(於香港註冊成立的有限公司)

如 閣下欲以本身名義登記將獲發行的香港發售股份，請使用本表格

- **聲明及陳述**此乃 閣下為本身或為其利益提出申請的人士所提出及擬提出的唯一申請；
- (如本申請為 閣下本身的利益提出) **保證** 閣下或作為 閣下代理的任何人士或任何其他人士不會亦不會為 閣下的利益以**白色或黃色**申請表格或向香港結算或向**白表eIPO**服務供應商發出電子認購指示而提出其他申請；及
- (如 閣下作為代理為另一人士的利益提出申請) **保證**
(i) 閣下(作為代理或為該人士利益)或該人士或任何其他作為該人士代理的人士不會亦不會以**白色或黃色**申請表格或向香港結算發出電子認購指示而提出其他申請及(ii) 閣下獲正式授權作為該人士的代理代為簽署本申請表格或發出電子認購指示。

如 閣下為個人申請人並合資格親身領取， 閣下不得授權任何其他人士代領。如 閣下為公司申請人並合資格派人領取， 閣下的授權代表須為合資格代理人，並須在表格上簽署。如 閣下為個人申請人並合資格親身領取， 閣下不得授權任何其他人士代領。如 閣下為公司申請人並合資格派人領取， 閣下的授權代表須為合資格代理人，並須在表格上簽署。

丁、授權書

如 閣下透過授權代理人提出申請，本公司及聯席全球協調人可按其認為合適的條件(包括出示獲授權證明)酌情接納或拒絕 閣下的申請。

釐定發售價及香港發售股份的分配

預期發售價於2020年10月16日(星期五)或前後釐定。申請人須繳付每股香港發售股份13.70港元的最高發售價，另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費。倘若本公司與聯席全球協調人(為其本身及代表包銷商)並無於2020年10月22日(星期四)或之前協定發售價，全球發售將不會進行。

截止登記認購申請前，概不處理香港發售股份的申請或配發任何香港發售股份。

本公司預期於2020年10月22日(星期四)在聯交所網站 www.hkexnews.hk 及本公司網站 www.simcere.com 公佈最終發售價、國際發售踴躍程度、香港公開發售申請水平及香港發售股份分配基準。分配結果以及獲接納申請人的香港身份證／護照／香港商業登記號碼(如適用)亦將於上述網站公佈。

在香港公開發售與國際發售之間分配發售股份將受招股書「全球發售的架構－香港公開發售－重新分配」一節所述調整規限。特別是，聯席全球協調人可將發售股份由國際發售重新分配至香港公開發售，以滿足根據香港公開發售作出的有效申請。根據聯交所發出的指引信HKEEx-GL91-18，倘有關重新分配並非根據上市規則第18項應用指引作出，則可由國際發售重新分配至香港公開發售的發售股份數目不得超過26,056,000股，佔全球發售下初步可供認購發售股份約10%，使香港公開發售項下可供認購的發售股份總數增至52,114,000股，佔發售股份約20%，及最終發售價須為招股書所載的指示性發售價範圍的低位數(即每股發售股份12.10港元)。

如 閣下成功申請認購香港發售股份(全部或部分)

如 閣下申請認購1,000,000股或以上香港發售股份， 閣下可於2020年10月22日(星期四)或吾等於報章通知的其他日期上午九時正至下午一時正親臨香港中央證券登記有限公司(地址為香港灣仔皇后大道東183號合和中心17樓1712-1716室)領取退款支票及／或股票。

Personal Data

Personal Information Collection Statement

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and its Hong Kong Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Cap. 486) (the “**Ordinance**”).

1. Reasons for the collection of your personal data

It is necessary for applicants and registered holders of securities to supply correct personal data to the Company or its agents and the Hong Kong Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the Hong Kong Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected, or in delay or the inability of the Company or its Hong Kong Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of share certificate(s) and/or refund cheque(s) to which you are entitled.

It is important that securities holders inform the Company and the Hong Kong Share Registrar immediately inaccuracies in the personal data supplied.

2. Purposes

The personal data of the securities holders may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque, where applicable, verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of securities’ holders including, where applicable, HKSCC Nominees;
- maintaining or updating the register of securities’ holders of the Company;
- verifying securities holders’ identities;
- establishing benefit entitlements of securities’ holders of the Company, such as dividends, rights issues, bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and securities’ holder profiles;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Share Registrar to discharge their obligations to securities’ holders and/or regulators and/or any other purposes to which the securities’ holders may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and its Hong Kong Share Registrar relating to the securities holders will be kept confidential but the Company and its Hong Kong Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company’s appointed agents such as financial advisers, receiving bankers and overseas principal share registrar;
- where applicants for securities request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Share Registrar in connection with their respective business operation;
- the Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any persons or institutions with which the securities’ holders have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

4. Retention of personal data

The Company and its Hong Kong Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access to and correction of personal data

Securities holders have the right to ascertain whether the Company or the Hong Kong Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Share Registrar have the right to charge a reasonable fee for the processing of such requests.

All requests for access to data or correction of data should be addressed to us, at our registered address disclosed in the “Corporate Information” section of the Prospectus or as notified from time to time, for the attention of the company secretary, or our Hong Kong Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form or by giving electronic application instructions to HKSCC, you agree to all of the above.

個人資料

個人資料收集聲明

此項個人資料收集聲明是向香港發售股份的申請人和持有人說明有關本公司及其香港股份過戶登記處有關個人資料和第486章《個人資料（私隱）條例》（「**條例**」）方面的政策和慣例。

1. 收集閣下個人資料的原因

證券申請人及登記持有人以本身名義申請證券或轉讓或受讓證券時或尋求香港股份過戶登記處的服務時，必須向本公司或其代理人及香港股份過戶登記處提供準確個人資料。

未能提供所要求的資料可能導致閣下申請證券被拒或延遲，或本公司或其香港股份過戶登記處無法落實轉讓或提供服務。此舉也可能妨礙或延遲登記或轉讓閣下成功申請的香港發售股份及／或寄發閣下應得的股票及／或退款支票。

證券持有人所提供的個人資料如有任何錯誤，須立